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Purpose: Indoxyl sulfate and p-cresyl sulfate are important protein-bound uremic retention solutes 
whose levels can be partially reduced by renal replacement therapy. These solutes originate from 
intestinal bacterial protein fermentation and are associated with cardiovascular outcomes and chronic 
kidney disease progression. The aims of this study were to investigate the levels of indoxyl sulfate and 
p-cresyl sulfate as well as the effect of probiotics on reducing the levels of uremic toxins in pediatric 
patients on dialysis. 
Methods: We enrolled 20 pediatric patients undergoing chronic dialysis; 16 patients completed 
the study. The patients underwent a 12-week regimen of VSL#3, a high-concentration probiotic 
preparation, and the serum levels of indoxyl sulfate and p-cresyl sulfate were measured before 
treatment and at 4, 8, and 12 weeks after the regimen by using fluorescence liquid chromatography. To 
assess the normal range of indoxyl sulfate and  p-cresyl sulfate we enrolled the 16 children with normal 
glomerular filtration rate who had visited an outpatient clinic for asymptomatic microscopic hematuria 
that had been detected by a school screening in August 2011.
Results: The baseline serum levels of indoxyl sulfate and p-cresyl sulfate in the patients on chronic 
dialysis were significantly higher than those in the children with microscopic hematuria. The baseline 
serum levels of p-cresyl sulfate in the peritoneal dialysis group were significantly higher than those in 
the hemodialysis group. There were no significant changes in the levels of these uremic solutes after 
12-week VSL#3 treatment in the patients on chronic dialysis. 
Conclusion: The levels of the uremic toxins p-cresyl sulfate and indoxyl sulfate are highly elevated 
in pediatric patients on dialysis, but there was no significant effect by probiotics on the reduction of 
uremic toxins in pediatric dialysis patients. Therefore, studies for other medical intervention to reduce 
uremic toxins are also necessary in pediatric patients on dialysis.
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Introduction
Loss of kidney function induces accumulation of a variety of substances that can 
cause uremia syndrome. These substances are small water-soluble solutes, protein-
bound solutes and middle-molecule solutes
1,2). Protein-bound solutes, such as indoxyl 
sulfate and p-cresyl sulfate, are excreted by the kidneys via proximal tubular secretion 
and they accumulate in the blood of patients with chronic kidney disease (CKD)
1,2). The 
conventional renal replacement therapies can only partially remove these protein-bound 
solutes as opposed to small water-soluble solutes, because they are bound to albumin
3,4). 
The average levels of p-cresyl sulfate in patients undergoing hemodialysis (HD) are 10 
times the normal levels
5). p-Cresol, which exists mainly as p-cresyl sulfate in blood, is 
generated by the partial breakdown of tyrosine and phenylalanine by intestinal obligate http://dx.doi.org/10.3345/kjp.2013.56.4.159
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or facultative anaerobes, and it is associated with infection, 
cardiovascular disease, and mortality
5,6). This solute depresses 
the respiratory burst activity of phagocytes and endothelial cell 
response to inflammatory cytokines. Indoxyl sulfate, an end 
product of bacterial metabolism of tryptophan, is considered to 
be a key player in increased glomerular sclerosis and progression 
of CKD
4,7,8). Indoxyl sulfate is known as to be involved in the 
pathogenesis of atherosclerosis. 
The production of these uremic solutes originates from bac-
terial protein fermentation in the intestine and is influenced 
by the intestinal environment such as intestinal flora and pH. 
The bowel environmental differences, including prolonged 
transit time in the colon, constipation, and abnormal intestinal 
flora, are usually observed in end-stage renal disease (ESRD) 
patients because of diet restriction and uremia. The bacterial 
composition of the intestines in ESRD patients is different from 
that of the normal population. The proportion of aerobic bacteria 
such as enterobacteria and enterococci in patients with HD is 
approximately 100 times the normal level
9). Since p-cresyl sulfate 
and indoxyl sulfate are mainly produced by these aerobes, 
generation of toxic microbial protein metabolites is increased in 
ESRD patients
9). To reduce the production of toxic metabolites 
originating from bacterial fermentation, it is important to 
modulate bacterial growth in the intestine. Probiotics are defined 
by the World Health Organization as living microorganisms 
that, when administered in an adequate amount, confer a 
health benefit on the host. Probiotics can help restore intestinal 
micro  flora by reducing proteolytic bacteria and increasing 
saccharolytic bacteria in addition to improving bowel habits. 
Finally, probiotics have been known to reduce uremic toxins in 
the blood by correcting the intestinal microflora
7,9). 
In recent studies, probiotics treatment has contributed to 
reduction of the serum level of protein-bound solutes, such as 
indoxyl sulfate and p-cresyl sulfate, in adult HD patients
8,10). 
However, there is little data regarding the levels of indoxyl 
sulfate and p-cresyl sulfate and the effects of probiotics on these 
uremic retention solutes in pediatric patients on dialysis.  
The aims of this study were to investigate 1) the levels of 
indoxyl sulfate and p-cresyl sulfate in pediatric patients on 
dialysis and the differences in these uremic toxins levels by 
dialysis modality, 2) the relationship between indoxyl sulfate 
and p-cresyl sulfate, 3) the effect of probiotics to reduce uremic 
toxins and their safety in pediatric patients on dialysis.
Materials and methods
1. Patients
For the study design, a minimal sample size calculation was 
made based on a statistical power of 80% and a significance 
level at 0.05 under two-tail analysis. According to the results, we 
enrolled the 20 pediatric patients on chronic dialysis from one 
dialysis unit located in Seoul, Republic of Korea, at the initiation 
of this trial. Finally, 16 patients completed the study during 12 
weeks. 
Five patients were on HD, and 11 patients were on peritoneal 
dialysis (PD). This study was conducted from December 2010 to 
May 2011. The exclusion criteria were: 1) patients who had been 
on dialysis for less than 3 months; 2) patients who had acute 
infectious disease, including acute gastroenteritis; 3) patients 
currently on antibiotic treatment.  
As there is no data for the normal range of indoxyl sulfate and 
p-cresyl sulfate in Korean children, we included 16 children as a 
control group, who visited the outpatient clinic for asymptomatic 
microscopic hematuria detected by school screening in August 
2011. They showed a normal range of serum urea nitrogen and 
creatinine.  
2. Study design
A single-center, prospective, nonrandomized, open-label 
study was designed. The 16 patients on chronic dialysis received 
VLS#3 once daily, 30 minutes after a meal for 12 weeks. 
VSL#3 is a high-concentration (450 billion viable cells/sachet) 
probiotic preparation of eight live freeze-dried bacterial species 
that are normal components of the human gastrointestinal 
microflora, including four strains of lactobacilli (Lactobacillus 
casei, Lactobacillus plantarum, Lactobacillus acidophilus, 
and Lactobacillus Delbrueckii subsp. bulgaricus), three strains 
of bifidobacteria (Bifidobacterium longum, Bifidobacterium 
breve, and Bifidobacterium infantis), and Streptococcus sali-
varius subsp. thermophilus. The dose given to patients is 
shown in Table 1. The dose was prescribed on the basis of the 
recommendation on the label and is approved by the Korea Food 
and Drug Administration. The patients were asked to answer 
a questionnaire regarding compliance, defecation, change in 
bowel habits, and adverse events during the study period when 
they visited the outpatient clinic or dialysis unit. There was 
no restriction on patients’ everyday diet, medication, or daily 
activities. None of the patients who completed the study used 
Table 1. Probiotic treatment doses
Age (yr) Weight (kg) Daily dose (packet; bacteria/day)
1–3   9–16 1/4 (225 billion)
4–6  17–23 1/2 (450 billion)
7–10  24–33 1 (900 billion)
11–14  34–53 1 + 1/2 (1,350 billion)
15–17  54–66 2 (1,800 billion)
The doses are based on the recommendation on the label. 161 http://dx.doi.org/10.3345/kjp.2013.56.4.159
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antibiotics during the study period.
 This study was approved by the ethics committee of Samsung 
Medical Center. All participants gave written informed consent. 
3. Laboratory evaluation 
After the patients provided informed consents, a baseline 
evaluation was made during the midweek dialysis session in 
HD patients or during the outpatient clinic visit in PD patients. 
All blood parameters were measured before the first intake of 
probiotics and 4, 8, and 12 weeks after taking VSL#3, which 
include blood urea nitrogen, creatinine, electrolyte, bicarbonate, 
parathyroid hormone, calcium, phosphate, uric acid, protein, 
albumin, aspartate aminotransferase, alanine aminotransferase, 
glucose, insulin, complete blood count, indoxyl sulfate, and 
p-cresyl sulfate. C-reactive protein and normalized protein 
catabolic rate (nPCR) were measured in patients on HD. Dialysis 
adequacy was evaluated by renal Kt/V and total Kt/V in 
patients on chronic dialysis. The serum levels of indoxyl sulfate 
and p-cresyl sulfate were measured by fluorescence liquid 
chromatography. 
4. Statistical analysis 
The descriptive data were expressed as the median. Laboratory 
data were expressed as the mean±standard deviation. Differences 
between patients and control subjects were evaluated using 
Mann-Whitney U-test. Sperman’s rank correlation test was 
used to analyze the correlation between serum levels of p-cresyl 
sulfate and indoxyl sulfate. Wilconxon signed-rank sum test 
was used for comparison of levels before and after probiotic 
administration in each patient group. P values less than 0.05 
were considered statistically significant. All statistical analyses 
were conducted using the IBM SPSS ver. 18.0 (IBM Co., Armonk, 
NY, USA). 
Table 2. Characteristics of controls and patients 
Characteristic Control subjects Hemodialysis group Peritoneal dialysis group
No. 16 5 11
Sex (male:female) 10:6 4:1 8:3
Age (yr) 12 (7–16) 8 (3–16) 15 (7–21)
Height (cm) 147.9 (130.4–169.9) 117.2 (98–157) 146.6 (110.6–170.7)
Body weight (kg) 44.1 (21.8–67.6) 22.5 (12.4–42) 46.1 (19.3–74.8)
Body mass index (kg/m
2) 19.6 (23.8–12.7) 14.9 (12.9–19.7) 17.1 (13.9–37.4)
Dialysis duration (mo) - 30 27
Values are presented as median (range).
Table 3. Laboratory findings for the controls and patients before probiotic treatment 
Variable Control Hemodialysis group Peritoneal dialysis group
Hemoglobin (g/dL)  13.4±1.11 8.9±0.99 10.2±1.11
Uric acid (mg/dL)  4.9±1.4 5.7±0.74 8.0±1.93
C-reactive protein (mg/dL)      - 1.1±0.76 -
Albumin (g/dL)  4.3±0.40 3.7±0.34 4.0±0.43
Calcium (mg/dL)  9.3±0.34 9.2±0.74 9.4±0.61
Phosphorous (mg/dL)  4.1±0.54 4.5±1.18 5.1±1.48
Alkaline phosphatase (U/L )  185.1±76.7 218.2±154.51 227.3±172.72
Blood urea nitrogen (mg/dL)  12.0±2.0 51.7±23.0 62.7±24.05
Creatinine (mg/dL)  0.6±0.12 5.3±2.23 9.6±6.60
Kt/V, total - 1.27±0.3 2.97±1.1
Renal - - 1.46±1.5
nPCR (g/kg/day) - 1.1±0.2 -
p-cresyl sulfate (µM) 3.2±1.44 55.18±67.79 142.85±59.06
Indoxyl sulfate (µM) 8.2±6.60 101.67±58.45 145.76±97.89
Values are presented as mean±standard deviation.
nPCR, normalized protein catabolic rate.http://dx.doi.org/10.3345/kjp.2013.56.4.159
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Results
1. Study population
Patient characteristics are summarized in Table 2. The median 
duration of dialysis at the time of the study was 30 months in the 
HD group and 27 months in the PD group. The PD patients were 
older and heavier than HD patients. There was no significant 
difference in the level of body mass index between the HD 
group and PD group. Table 3 summarizes the baseline laboratory 
findings of the control and patient groups prior to starting the 
probiotics. There was no significant difference in the level of 
blood urea nitrogen between the HD group and PD group. Dialysis 
adequacy seemed to meet the Kidney Disease Outcomes Quality 
Initiative guideline. The level of nPCR was above 1.0 g/kg/day in 
HD patients and the protein intake seemed to be adequate. There 
was no significant difference in the laboratory findings before and 
after the probiotics treatment in HD and PD patients.
2. Serum concentrations of indoxyl sulfate and p-cresyl sulfate 
before taking VSL#3
Comparisons of baseline levels of p-cresyl sulfate and in-
doxyl sulfate between the control group and patient group are 
summarized in Table 4 and depicted in Fig. 1. The serum levels 
of p-cresyl sulfate and indoxyl sulfate in the patient groups were 
significantly higher than those in the control group before taking 
VSL#3. The serum level of p-cresyl sulfate in the PD group was 
significantly higher than that of the HD group (142.85±59.06 
µM vs. 55.18±67.79 µM, P=0.047). There was no significant 
difference in the serum level of indoxyl sulfate between the HD 
group and the PD group.
In the correlation analysis, there was no correlation between 
serum indoxyl sulfate and p-cresyl sulfate in pediatric patients 
on dialysis.
3. Efficacy evaluation
The adherence to the study was excellent, and no patient 
discontinued probiotics treatment during the study period, 
except 4 patients, who were excluded from the study because 
of kidney transplantation or taking antibiotics. The results of 
the questionnaires during the outpatient clinic showed that the 
prescribed dose was well tolerated, and there were no serious 
adverse effects during VSL#3 therapy. Intention to treat analysis of 
changes in serum indoxyl sulfate and p-cresyl sulfate at 12 weeks 
demonstrated that there were no significant changes in the level 
of p-cresyl sulfate and indoxyl sulfate in patients on HD and PD 
during VSL#3 treatment (Table 4). 
Discussion
In this study, we found that the serum levels of protein-bound 
solutes, such as p-cresyl sulfate and indoxyl sulfate, in pediatric 
Table 4. Effects of probiotic treatment on serum levels of uremic toxins
Hemodialysis group P value* Peritoneal dialysis group P value*
p-cresyl sulfate (µM)
Before treatment 55.18± 67.79 142.85±59.06
4-wk  103.31±149.51 NS 106.70±60.78 NS
8-wk 64.34±80.45 NS 140.85±80.56 NS
12-wk 49.78±19.07 NS 131.38±79.57 NS
Indoxyl sulfate (µM)
Before treatment 101.65±58.45 145.76±97.89
4-wk  119.43±71.45 NS 132.81±123.63 NS
8-wk 116.67±76.40 NS 148.50±107.73 NS
12-wk 98.71±53.64 NS 147.93±115.62 NS
Values are presented as mean±standard deviation.
NS, not significant.
*Comparison with the basal levels of uremic toxins.
µm 
Fig. 1. Serum levels of indoxyl sulfate and p-cresyl sulfate in controls and 
patients. PD, peritoneal dialysis; HD, hemodialysis.163 http://dx.doi.org/10.3345/kjp.2013.56.4.159
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patients on chronic dialysis were much higher than those of 
unbound solutes such as urea. Whereas the average levels of 
serum urea were about 5 times the levels in the control group, 
the average levels of serum p-cresyl sulfate in our HD group 
were about 17 times the levels in the control group. Previously 
reported serum concentrations of p-cresyl sulfate in adult 
patients on HD were about 10 to 12 times the levels in healthy 
volunteers
5,11). This result possibly suggests that the clearance of 
protein bound solutes was much lower in pediatric patients than 
that in adult patients. It is possible that the age or body size also 
might affect the serum levels of p-cresyl sulfate in addition to 
the dialysis modality. We suspect that the high protein diet, the 
bowel environment, and dialysis adequacy in pediatric patients 
could be related to the higher protein-bound uremic toxin 
levels compared to those of adult patients. The serum levels of 
these two toxins can be evaluated by various kinds of liquid 
chromatography and the parallel investigation by the same 
method is needed in adults and pediatric patients to evaluate the 
difference of the serum levels of p-cresyl sulfate regarding to 
age
3,4,6,8). 
In our results, the serum p-cresyl sulfate level of PD group 
was higher than HD group. It has been known that the clearance 
of protein-bound solutes is lower for PD than for HD
12,13). The 
clearance of protein-bound solutes during HD can maximize 
the gradient by high dialysate flow. However, the clearance of 
protein-bound protein in PD cannot easily be increased, and 
the volume of dialysate and membrane mass transfer area 
coefficient are much lower for PD than for HD
14,15). Previous 
studies found that residual renal function plays a more important 
role in the clearance of protein-bound protein than in the clear-
ance of water-soluble molecules in PD patients, and residual 
renal function contributed to more than two-thirds of p-cresyl 
sulfate clearance
16,17). In recent years, it has been shown that 
serum indoxyl sulfate and p-cresyl sulfate might be involved 
in vascular damage and cardiovascular mortality in CKD
18). In 
addition to cardiovascular disease, it has been known that serum 
indoxyl sulfate and p-cresyl sulfate levels might predict the risk 
of renal progression in patients having different stages of CKD
18). 
Because the pediatric ESRD patients tend to receive PD instead 
of HD, the clinical outcomes by protein bound solutes should be 
evaluated regarding the dialysis modality in pediatric patients.
In our study, there was no correlation between serum in-
doxyl sulfate and p-cresyl sulfate in pediatric patients on 
dialysis. Although indoxyl sulfate and p-cresyl sulfate share 
some characteristics, such as the albumin-binding site and 
low clearance by dialysis, it is known that indoxyl sulfate and 
p-cresyl sulfate serum concentrations are not associated, and our 
results were compatible with the previous report
6). 
In our study, there were no significant changes in the levels 
of p-cresyl sulfate and indoxyl sulfate in patients on HD 
and PD during VSL#3 therapy. The small sample size of 16 
patients raised concerns as to its statistical power. More than 
21 participants are needed for a statistical power of 80% and 
a significance level at 0.05 under two-tail analysis. Although 
we tried to enroll more than 21 pediatric patients on chronic 
dialysis, a total of 20 patients participated at the initiation of this 
trial and 4 patients were dropped during 3 months of follow-up. 
Two patients were dropped due to kidney transplantation and 
the two other patients were given antibiotics during the trial. 
We guess that not only the factors associated with probiotics, 
but also other factors such as carbohydrate to protein ratio, 
colonic transit, other medications, dialysis adequacy, or residual 
renal function could influence uremic toxin levels. Both the 
form and dosage of probiotics can affect the serum levels of 
uremic toxins. Since probiotics are more effective in the gastro-
resistant seamless capsule, the form of probiotics can influence 
uremic toxin levels. The bacterial components of VSL#3 remain 
viable in human ileostomy effluent and, in vivo, VSL#3 bacteria 
are able to survive passage through the ileocecal tract and 
reach the large bowel
19). Analysis of fecal samples obtained 
from healthy volunteers showed that the main components of 
VSL#3 persisted in the gastrointestinal tract during treatment 
and a short period after discontinuation of VSL#3
20). Recently, 
synbiotics, which combine probiotics and prebiotics, have been 
used to improve the intestinal environment and bowel habits 
and reduce uremic toxins
10). Prebiotics include carbohydrate 
fibers called oligosaccharides, which remain in the digestive tract 
and stimulate the growth of beneficial bacteria
10). Synbiotics 
treatment is known to be more effective for improving intestinal 
environments in various medical conditions, including ESRD 
patients than probiotics only
10). Synbiotics treatment is not avail-
able for pediatric patient. We used the usual dose of VSL#3, 
which is recommended on the label. There were no serious 
adverse effects, and this dosage was well tolerated in our 
patients. We guess that the effects of VSL#3 can be significant in 
patients on dialysis if the treatment dose is titrated on the basis 
of tolerability and stool analysis. 
Generation of uremic solutes can be modulated by increasing 
carbohydrates and reducing protein intake. In our study, nPCR 
was investigated at baseline, 4 weeks, 8 weeks, and 12 weeks in 
patients with HD and it seemed that the levels of nPCR decreased 
during the study from 1 g/kg/day to 0.9 g/kg/day. This finding 
suggested that the protein intake in HD patients might influence 
the levels of p-cresyl sulfate and indoxyl sulfate. Colonic transit 
time may also affect the generation of uremic toxins. Prolonged 
colonic transit might result in increased generation and absorp-
tion of uremic toxins. Most patients reported that their bowel 
habits improved, but we could not evaluate the change in 
bowel habits by score. Although we excluded the patients who 
were taking antibiotics, other drug therapies such as phosphate http://dx.doi.org/10.3345/kjp.2013.56.4.159
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binders can affect the colonic environment
7,21). Although the 
change was not statistically significant, the serum level of 
p-cresyl sulfate decreased in the HD and PD group after VSL#3 
therapy. The serum level of p-cresyl sulfate increased from the 
baseline at 4 weeks in patients on HD and it is possible that the 
dialysis adequacy was insufficient during that period in a few 
patients. Three patients showed lower levels of total Kt/V below 
1.0 at 4 weeks, which recovered to baseline at 8 and 12 weeks 
and the serum level of p-cresyl sulfate increased in these patients 
at 4 weeks. 
In conclusion, uremic toxins such as p-cresyl sulfate and in-
doxyl sulfate are highly elevated in pediatric patients on dialysis, 
and p-cresyl sulfate levels in PD patients were significantly 
higher than those in HD patients. In this study, there was no 
significant effect by probiotics on the reduction of uremic toxins 
in pediatric dialysis patients. Future studies, including more 
pediatric patients on dialysis, are needed to evaluate the levels 
and clinical outcomes of p-cresyl sulfate and indoxyl sulfate 
and compare the difference of these toxins regarding the dialysis 
modality. It is also known that uremic toxins such as p-cresyl 
sulfate and indoxyl sulfate can be reduced by the oral charcoal 
adsorbent AST-120 (Kremezin, Kureha Co., Tokyo, Japan), which 
has been proven to be capable of absorbing uremic toxins and 
attenuating the oxidative stress generated by them
18). Therefore, 
studies for other medical intervention such as charcoal adsorbent 
to reduce uremic toxins are also necessary in pediatric patients 
on dialysis. 
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